Perampanel

K K Jain MD (Dr. Jain is a consultant in neurology and has no relevant financial relationships to disclose.)
Originally released June 26, 2013; last updated July 24, 2017; expires July 24, 2020

Historical note and terminology

Perampanel, an aminomethyl propionic acid (AMPA) receptor antagonist, has been studied for various clinical indications, including epilepsy and Parkinson disease. The drug is currently approved in the United States and the European Union as adjunct treatment for control of partial-onset seizures in those who are 12 years of age and older. Perampanel has the potential for addiction. The Drug Enforcement Administration has placed perampanel into schedule III drug (ie, persons who handle this drug are subject to regulatory controls and administrative, civil, and criminal sanctions applicable to schedule III controlled substances).

The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.

If you are a subscriber, please log in.

If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.

If you have never registered before, click Learn More about MedLink Neurology  or view available Service Plans.